基因表达检测时代:导管原位癌全乳切除腋窝分期结局
单中心回顾性研究纳入175例术前导管原位癌行全乳切除患者,术后发现38例浸润癌,仅3例pT1患者前哨淋巴结阳性。仅1例因腋窝分期结果接受额外放疗,无患者仅因前哨淋巴结活检结果接受化疗,提示腋窝分期对辅助治疗影响有限。
要点
- 术前导管原位癌行全乳切除者中,约20%术后升级为浸润癌。
- 仅1例因前哨淋巴结活检结果接受额外放疗,无患者仅因此接受化疗。
- 前哨淋巴结活检可能并非所有导管原位癌全乳切除患者的必需。
核心结论
- 导管原位癌全乳切除时常规前哨淋巴结活检对辅助治疗决策影响有限,可能并非每位患者必需。
主要发现
- 175例中术后发现38例浸润癌,pT1恶性肿瘤中3例前哨淋巴结阳性。
- 仅1例因腋窝分期结果被推荐额外放疗,无患者仅因前哨淋巴结活检结果被推荐化疗。
临床怎么用
- 对术前导管原位癌拟行全乳切除者,可个体化评估前哨淋巴结活检必要性,尤其低级别有利生物学特征者。
局限性
- 单中心回顾性设计,样本量有限,结论需更大样本验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Approximately 20% of women diagnosed with ductal carcinoma in situ on core biopsy will be upstaged to invasive disease on final pathology. Sentinel lymph node biopsy at the time of mastectomy for ductal carcinoma in situ is the current standard of care. However, the underlying invasive cancer is frequently of low grade with favorable biology, bringing into question the necessity of sentinel lymph node biopsy to help guide clinical treatment recommendations. The primary study objective was to determine how often sentinel lymph node biopsy at the time of mastectomy for ductal carcinoma in situ alters adjuvant therapy recommendations. METHODS: A single-institution cancer registry retrospectively identified women treated with mastectomy for a preoperative diagnosis of ductal carcinoma in situ between November 2017 and November 2023, excluding those with a previous history of ipsilateral breast cancer. The impact of pathologic nodal status on adjuvant treatment was evaluated. RESULTS: The study population included 175 patients with a total of 38 invasive cancers identified. Of those with pT1 malignancies, 3 had a positive sentinel node. One patient was recommended for additional adjuvant treatment, in the form of radiation therapy, as a result of axillary staging. No patients were recommended for chemotherapy based solely on sentinel lymph node biopsy results. CONCLUSION: Despite current recommendations to perform sentinel lymph node biopsy in ductal carcinoma in situ treated with mastectomy in the event invasive cancer is identified on final pathology, our outcomes suggest nodal status has limited impact on adjuvant therapy offerings. These findings indicate that sentinel lymph node biopsy may not be requisite for every patient undergoing mastectomy for ductal carcinoma in situ.
引用
- Levine A, Wood H, Omole I, et al. Axillary staging outcomes in women undergoing mastectomy for ductal carcinoma in situ in the era of gene expression assays. Surgery. 2025. PMID: 41353075. doi:10.1016/j.surg.2025.109909
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。